Genentech, Inc.

F. Hoffmann-la Roche Ag

Simon Charles Goodacre

Jun Liang

Nicholas Charles Ray

Birong Zhang

Karen Williams

Xiaojing Wang

Daniel Fred Ortwine

Sharada Shenvi Labadie

Wei Li

Hazel Joan Dyke

Mark Edward Zak

Joseph P Lyssikatos

Huifen Chen

Steven R Magnuson

Lewis J Gazzard

Calum MacLeod

Nicholas D Smith

Po-wai Yuen

Steven P Govek

Mehmet Kahraman

Johnny Yasuo Nagasawa

Emanuela Gancia

Mark S Stanley

Vickie H Tsui

Rohan V Mendonca

Tao Wang

John Gary Montana

Stephen Colin Price

F Anthony Romero

Snahel Patel

Wendy Lee

Vickie Hsiao-Wei Tsui

James John Crawford

Guiling Zhao

Po-Wai Yuen

Kirk D Robarge

Andiliy Gokching Lai

Paul Gibbons

Christine Edwards

Kwong Wah Lai

Yun-Xing Cheng

Jason R Zbieg

Charles Ellwood

Jun M Li

Terry Kellar

Yingjie Lai

Samuel S Kintz

Calum Macleod

Toby Jonathan Blench

Jiangpeng Liao

Aihe Zhou

Gregory Hamilton

Joy Drobnick

Zhiguo Liu

Matthew W Cartwright

John Wai

Liang Bao

Jun Li

Anthony F Romero

Tommy Lai

Rongbao Hua

Mohammed Sajad

Po-Wei Yuen

Limin Cheng

Rohan Mendonca

Jason Zbieg

John Sui-Man Wai

Samuel Kibtz

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure:

Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof

Compounds of Formula (I): and salts thereof, and methods of use as Janus kinase inhibitors are described herein.

Therapeutic compounds, compositions and methods of use thereof

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure:  and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and

Heteroaryl estrogen receptor modulators and uses thereof

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Heterocyclic estrogen receptor modulators and uses thereof

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.

Triazolopyridine compounds, compositions and methods of use thereof

Described herein are compounds that are estrogen receptor modulators of Formula (I): 

Estrogen receptor modulators and uses thereof

Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof

The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

1,7-diazacarbazoles and methods of use

The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, X, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of using the compound or composition in therapy. 

Pyrazolopyridine compounds, compositions and methods of use

Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R, Rand Rare as defined herein.

Methods of use of diazacarbazoles for treating cancer

Provided are compounds of Formula I, stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, wherein A, X, R, R, Rand Rare defined herein, a pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, and methods of manufacturing a compound of Formula I. 

Azabenzothiazole compounds, compositions and methods of use

The invention relates to 1,7-diazacarbazole compounds of Formula (I), which are useful as kinase inhibitors, more specifically useful as checkpoint kinase I (chk1) inhibitors, thus useful as cancer therapeutics. 

Diazacarbazoles and methods of use

Growing community of inventors

Harlow, United Kingdom

Simon Charles Goodacre